Product Description: Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity[1][2].
Applications: COVID-19-anti-virus
Formula: C27H37N3O7S
References: [1]Dominique L N G Surleraux, et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem. 2005 Mar 24;48(6):1813-22./[2]Yasuhiro Koh, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9.
CAS Number: 206361-99-1
Molecular Weight: 547.66
Compound Purity: 99.91
Research Area: Infection; Inflammation/Immunology
Solubility: DMSO : ≥ 100 mg/mL
Target: HIV;HIV Protease
Deutsch
English
